Ranbaxy's Dewas and Paonta units under DCGI scanner

Biospectrum Singapore: Days after the Drug Controller General of India (DCGI) approved Cadila Healthcare's new chemical entity, Lipaglyn, for launch in India, the company announced its plans for the year 2020.Cadila Healthcare said in ...

New Delhi: The Drug Controller General of India (DCGI) is conducting a "focussed scrutiny" of medicines sold by Ranbaxy and some other drug makers. The drug regulator has, however, said that it remains confident of the quality standards of Indian ...

Soma Das , ET Bureau | 7 Jun, 2013, 05.08AM IST Post a Comment Clearly, questions are being raised on the quality of drugs after this episode, but we cannot have a knee-jerk reaction to this sensitive case, says Keshav Desiraju. The Drug Controller General of ...

In a bid to further streamline the functioning of the Central Drugs Standard Control Organisation, the Drugs Controller General of India (DCGI) has delegated the power of licensing authority in the head office to six senior officials for timely ...

Admitting that all drug applications and dossiers filed by Ranbaxy Laboratories in the US will be examined by the authorities, Drug Controller General of India (DCGI) Dr G N Singh said that all approvals given to its drugs in India were in order and ...

NEW DELHI: India's drug regulator is working on a clear policy on how it should respond to safety alerts by foreign regulators on medicines manufactured by Indian companies after two of the country's biggest drug manufacturers landed in trouble with ...

Text size Print Forward By Zachary Brennan+ 13-May-2013 Related tags: , , India, Clinical trials, CDSCO, DCGI Related topics: Clinical trial sites in India will be inspected at least once a year under a new regulatory plan issued by the CDSCO. Each ...

CDSCO's list was so full of inaccuracies that the parliamentary committee directed Drug Controller General of India (DCGI) to remove it from its website immediately.